ArticleCurrent research in immunology2021
Short chain fatty acids (SCFAs) improves TNBS-induced colitis in zebrafish.
Article in Current research in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Anti-inflammatory and protective effects of Aloe vera on intestinal function in zebrafish.Journal of molecular histology · 2026Article
- Article
- Neuroprotective role ofFrontiers in nutrition · 2026Article
- Effect of quorum quenching enzyme YtnP on immune response and intestinal microbiota inFrontiers in microbiology · 2026Article
- Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways.Marine drugs · 2025Article
- The Future Exploring of Gut Microbiome-Immunity Interactions: From In Vivo/Vitro Models to In Silico Innovations.Microorganisms · 2024Review
- A review on current advancement in zebrafish models to study chronic inflammatory diseases and their therapeutic targets.Heliyon · 2024Review
- Animal models of inflammatory bowel disease: category and evaluation indexes.Gastroenterology report · 2024Review
- Health benefits of butyrate and its producing bacterium,Fish and shellfish immunology reports · 2023Article
- The metabolites of lactic acid bacteria: classification, biosynthesis and modulation of gut microbiota.Microbial cell (Graz, Austria) · 2023Review
- Small fish, big discoveries: zebrafish shed light on microbial biomarkers for neuro-immune-cardiovascular health.Frontiers in physiology · 2023Review
- Combination Therapy with Indigo and Indirubin for Ulcerative Colitis via Reinforcing Intestinal Barrier Function.Oxidative medicine and cellular longevity · 2023Article
- Zebrafish: an efficient vertebrate model for understanding role of gut microbiota.Molecular medicine (Cambridge, Mass.) · 2022Review
- Designing Biological Microsensors with Chiral Nematic Liquid Crystal Droplets.ACS applied materials & interfaces · 2022Article
- Anti-inflammatory actions of acetate, propionate, and butyrate in fetal mouse jejunum cultures ex vivo and immature small intestinal cells in vitro.Food science & nutrition · 2022Article
- Atractylone Alleviates Ethanol-Induced Gastric Ulcer in Rat with Altered Gut Microbiota and Metabolites.Journal of inflammation research · 2022Article
- Xuedan Sustained Release Pellets Ameliorate Dextran Sulfate Sodium-Induced Ulcerative Colitis in Rats by Targeting Gut Microbiota and MAPK Signaling Pathways.Frontiers in pharmacology · 2022Article
- Different wild type strains of zebrafish show divergent susceptibility to TNBS-induced intestinal inflammation displaying distinct immune cell profiles.Current research in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The short-chain fatty acids (SCFAs) are metabolites originated from the fermentation of dietary fibers and amino acids produced by the bacteria of the intestinal microbiota. The most abundant SCFAs, acetate, propionate, and butyrate, have been proposed as a treatment for inflammatory bowel diseases (IBDs) due to their anti-inflammatory properties. This work aimed to analyze the effects of the treatment of three combined SCFAs in TNBS-induced intestinal inflammation in zebrafish larvae. Here, we demonstrated that SCFAs significantly increased the survival of TNBS-exposed larvae, preserved the intestinal endocytic function, reduced the expression of inflammatory cytokines and the intestinal recruitment of neutrophils caused by TNBS. However, SCFAs treatment did not appear to avoid TNBS-induced tissue damage in the intestinal wall and did not restore the number of mucus-producing goblet cells. Finally, exposure to TNBS induced dysbiosis of the microbiota with an increase in Betaproteobacteria and Actinobacteria, while the treatment with SCFAs maintained these population levels similar to control. Thus, we demonstrate that the treatment of three combined SCFAs presented anti-inflammatory properties previously seen in mammals, opening an opportunity to use zebrafish to explore the potential benefit of these and other metabolites to treat inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.